IL122984A0 - Treatment of attention-deficit/ hyperactivity disorder - Google Patents

Treatment of attention-deficit/ hyperactivity disorder

Info

Publication number
IL122984A0
IL122984A0 IL12298496A IL12298496A IL122984A0 IL 122984 A0 IL122984 A0 IL 122984A0 IL 12298496 A IL12298496 A IL 12298496A IL 12298496 A IL12298496 A IL 12298496A IL 122984 A0 IL122984 A0 IL 122984A0
Authority
IL
Israel
Prior art keywords
deficit
attention
treatment
hyperactivity disorder
hyperactivity
Prior art date
Application number
IL12298496A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9525909.9A external-priority patent/GB9525909D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL122984A0 publication Critical patent/IL122984A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL12298496A 1995-07-24 1996-07-18 Treatment of attention-deficit/ hyperactivity disorder IL122984A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US137395P 1995-07-24 1995-07-24
US634995P 1995-11-08 1995-11-08
GBGB9525909.9A GB9525909D0 (en) 1995-12-19 1995-12-19 Treatment of attention-defecit/hyperactivity disorder
PCT/US1996/012047 WO1997003665A1 (en) 1995-07-24 1996-07-18 Treatment of attention-deficit/hyperactivity disorder

Publications (1)

Publication Number Publication Date
IL122984A0 true IL122984A0 (en) 1998-08-16

Family

ID=27268037

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12298496A IL122984A0 (en) 1995-07-24 1996-07-18 Treatment of attention-deficit/ hyperactivity disorder

Country Status (14)

Country Link
EP (1) EP0756869A3 (de)
JP (1) JPH11510143A (de)
KR (1) KR19990035817A (de)
CN (1) CN1195287A (de)
AU (1) AU709704B2 (de)
CA (1) CA2227410A1 (de)
CZ (1) CZ16798A3 (de)
EA (1) EA000856B1 (de)
IL (1) IL122984A0 (de)
MX (1) MX9800589A (de)
NO (1) NO980251D0 (de)
NZ (1) NZ313076A (de)
WO (1) WO1997003665A1 (de)
YU (1) YU43996A (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
JP2001517628A (ja) * 1997-09-23 2001-10-09 イーライ・リリー・アンド・カンパニー 注意欠陥／多動障害の治療法
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
US6586427B2 (en) 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
CZ297346B6 (cs) * 1998-04-09 2006-11-15 Pharmacia & Upjohn Company Pouzití reboxetinu pro výrobu léku k lécbe nervových poruch
AU2003269923A1 (en) 2002-08-23 2004-03-11 Eli Lilly And Company 2- (phenoxymethyl)- and 2- (phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
GB0219687D0 (en) * 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
WO2004103356A2 (en) * 2003-05-15 2004-12-02 Eli Lilly And Company Treatment of emotional dysregulation
US20070032554A1 (en) * 2003-08-27 2007-02-08 Elililly And Company A Corporation Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors
JP6362601B2 (ja) 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
MX2017011459A (es) 2015-03-06 2018-04-24 Auspex Pharmaceuticals Inc Metodos para el tratamiento de trastornos del movimiento involuntario anormal.
JP2020029447A (ja) * 2018-06-25 2020-02-27 大原薬品工業株式会社 腸溶性高分子及び抗付着剤を含有する顆粒

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
EP0537915B1 (de) * 1991-09-27 1995-07-12 Eli Lilly And Company N-Alkyl-3-phenyl-3-(2-alkylthiophenoxy)Propylamine als Norepinephrineinhibitoren
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
ES2077358T3 (es) * 1992-10-08 1995-11-16 Lilly Co Eli N-alquil-3-fenil-3-(2-alquiltiofenoxi)propilaminas.
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
US5696168A (en) * 1995-07-24 1997-12-09 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder

Also Published As

Publication number Publication date
EA199800152A1 (ru) 1998-08-27
CN1195287A (zh) 1998-10-07
KR19990035817A (ko) 1999-05-25
CZ16798A3 (cs) 1998-11-11
NZ313076A (en) 1999-11-29
WO1997003665A1 (en) 1997-02-06
CA2227410A1 (en) 1997-02-06
JPH11510143A (ja) 1999-09-07
NO980251L (no) 1998-01-20
MX9800589A (es) 1998-04-30
AU6506196A (en) 1997-02-18
YU43996A (sh) 1999-06-15
EP0756869A3 (de) 1999-06-16
NO980251D0 (no) 1998-01-20
EA000856B1 (ru) 2000-06-26
EP0756869A2 (de) 1997-02-05
AU709704B2 (en) 1999-09-02

Similar Documents

Publication Publication Date Title
HUP9801283A3 (en) Use of tomoxetin for the production of medicaments against attention-deficit/hyperactivity disorder
AU9214498A (en) Treatment of attention-deficit/hyperactivity disorder
GB2298440B (en) Well treatment
GB2304196B (en) Electroconvulsive therapy
ZA957483B (en) Compounds and methods for the treatment of cancer
IL134718A0 (en) Treatment of conduct disorder
EP0795035A4 (de) Bearbeitung von häuten
IL122984A0 (en) Treatment of attention-deficit/ hyperactivity disorder
GB9519033D0 (en) Treatment
HK1120494A1 (en) Novel compounds and methods for synthesis and therapy
HK1016964A1 (en) Benzamides for neurodegenerative disorder treatment
ZA962689B (en) Benzamides for neurodegenerative disorder treatment
GB2309979B (en) Diamond treatment
ZA966129B (en) Treatment of attention-deficit/hyperactivity disorder.
GB9525909D0 (en) Treatment of attention-defecit/hyperactivity disorder
GB9507825D0 (en) Method of treatment
GB9415902D0 (en) Method of treatment
GB9407335D0 (en) Method of treatment
GB9503200D0 (en) Methods of treatment
GB9414652D0 (en) Method of treatment
GB9507082D0 (en) Diamond treatment
GB9510065D0 (en) Treatment
ZA964220B (en) Treatment of wastewater
ZA959978B (en) Intensive therapy bed
GB9524086D0 (en) Novel treatment